Cargando…

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report

BACKGROUND: Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. The presence of ctDNA in the blood is a result of biological processes, namely tumour cell apoptosis and/or necrosis, and can be used to monito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calapre, Leslie, Warburton, Lydia, Millward, Michael, Gray, Elin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857141/ https://www.ncbi.nlm.nih.gov/pubmed/31727009 http://dx.doi.org/10.1186/s12885-019-6336-3

Ejemplares similares

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
por: Warburton, Lydia, et al.
Publicado: (2020)

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
por: Marsavela, Gabriela, et al.
Publicado: (2021)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
por: Duffy, Michael J., et al.
Publicado: (2022)

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
por: Marsavela, Gabriela, et al.
Publicado: (2020)

Detection of metastases using circulating tumour DNA in uveal melanoma
por: Beasley, Aaron B., et al.
Publicado: (2023)

Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
por: Gilson, Pauline, et al.
Publicado: (2021)

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma
por: Beasley, Aaron, et al.
Publicado: (2018)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
por: Calapre, Leslie, et al.
Publicado: (2018)

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
por: Pender, Alexandra, et al.
Publicado: (2020)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
por: Marczynski, Gabriella Taques, et al.
Publicado: (2020)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
por: Lim, Minji, et al.
Publicado: (2018)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
por: Gabriel, Emmanuel, et al.
Publicado: (2018)

Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis
por: Zheng, Yang, et al.
Publicado: (2021)

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
por: Fitzgerald, Sandra, et al.
Publicado: (2023)

Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
por: Gray, Elin S, et al.
Publicado: (2015)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Ultrasensitive tumour‐agnostic non‐invasive detection of colorectal cancer recurrence using ctDNA methylation
por: Xiao, Yu, et al.
Publicado: (2022)

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors
por: Pedersen, Jesper Geert, et al.
Publicado: (2020)

ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
por: Masfarré, Laura, et al.
Publicado: (2021)

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
por: Seremet, Teofila, et al.
Publicado: (2019)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA
por: He, Na, et al.
Publicado: (2018)

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer
por: Bai, Fei, et al.
Publicado: (2023)

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
por: Lyu, Mengyuan, et al.
Publicado: (2019)

Usefulness of BRCA and ctDNA as Prostate Cancer Biomarkers: A Meta-Analysis
por: Domrazek, Kinga, et al.
Publicado: (2023)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bqqjjgtknhtbpau1tedtimsfv1